Abstract:Despite advances in the treatment of acute myeloid leukemia (AML), relapse is still widely observed and represents the major cause of death among patients with AML. Treatment options in the relapse setting are limited, still relying predominantly on allogeneic hematopoietic stem cell transplantation (allo-HSCT) and cytotoxic chemotherapy, with poor outcomes. Novel targeted and venetoclax-based combinations are being investigated and have shown encouraging results. Immune checkpoint inhibitors in combination with low-intensity chemotherapy demonstrated encouraging response rates and survival among patients with relapsed and/or refractory (R/R) AML, especially in the pre- and post-allo-HSCT setting. Blocking the CD47/SIRPα pathway is another strategy that showed robust anti-leukemic activity, with a response rate of around 70% and an encouraging median overall survival in patients with newly diagnosed, higher-risk myelodysplastic syndrome and patients with AML with a TP53 mutation. One approach that was proven to be very effective in the relapsed setting of lymphoid malignancies is chimeric antigen receptor (CAR) T cells. It relies on the infusion of genetically engineered T cells capable of recognizing specific epitopes on the surface of leukemia cells. In AML, different CAR constructs with different target antigens have been evaluated and demonstrated safety and feasibility in the R/R setting. However, the difficulty of potently targeting leukemic blasts in AML while sparing normal cells represents a major limitation to their use, and strategies are being tested to overcome this obstacle. A different approach is based on endogenously redirecting the patient’s system cells to target and destroy leukemic cells via bispecific T-cell engagers (BiTEs) or dual antigen receptor targeting (DARTs). Early results have demonstrated the safety and feasibility of these agents, and research is ongoing to develop BiTEs with longer half-life, allowing for less frequent administration schedules and developing them in earlier and lower disease burden settings.

Emerging agents for treatment of the relapsed/refractory multiple myeloma: reports from the 56th American Society of Hematology annual meeting

Bispecific Antibody Treatment of Multiple Myeloma: Latest Updates from the 2022 ASH Annual Meeting

Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia

Advances in the Treatment of Multiple Myeloma: Reports from the 56th American Society of Hematology Annual Meeting

Clinical Management of the Multiple Myeloma: Reports from the 56th American Society of Hematology Annual Meeting

Emerging agents and regimens for multiple myeloma

Progress in the research and treatment of relapsed and refractory multiple myeloma

Multiple myeloma, immunotherapy and minimal residual disease

The 56th American Society of Hematology Annual Meeting: Advances in Clinical Trials on Relapse/refractory Acute Myeloid Leukemia

Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma

Therapeutic progress in relapsed/refractory multiple myeloma

Treatment Strategies for Relapsed/refractory Multiple Myeloma

Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018

Report on Recent Progress of Multiple Myeloma in the 54th ASH Annual Meeting

Recent advance of small-molecule drugs for clinical treatment of multiple myeloma

Advances in the treatment of relapsed/refractory marginal zone lymphoma

Targeting Acute Myeloid Leukemia Stem Cells: Current Therapies in Development and Potential Strategies with New Dimensions

Research Progress on Myelodysplastic Syndromes:Report of the 2011 Annual Meeting of American Society of Hematology

Progress in the Diagnosis and Immunotherapy of Multiple Myeloma

An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!

Multiple Myeloma Therapy: Emerging Trends and Challenges